News
Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers: Here's What Investors Need to Know
Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell the weight-loss drug Wegovy. Novo Nordisk revealed on Monday that it will no longer work with Hims & Hers,
Zacks Investment Research on MSN2h
Hims & Hers Health (HIMS) Loses 22.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerA downtrend has been apparent in Hims & Hers Health, Inc. (HIMS) lately with too much selling pressure. The stock has ...
The loss of its ability to sell Wegovy is a significant hit to Hims & Hers' business. The massive drop today in its stock ...
Hims & Hers Health, Inc. sees 38% YoY subscriber growth, driven by 70% choosing personalized treatments. Click for my updated ...
Zacks Investment Research on MSN1d
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should KnowHims & Hers Health, Inc. (HIMS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea ...
Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower Monday after Novo Nordisk A/S (NYSE:NVO) terminated its ...
Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending ...
Hers provides prescription medication and support for weight loss, hair growth, sexual health, and more. Learn more about this telehealth company.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback